High levels of merger and acquisition activity will be the big theme of year for biotech, says Morningstar's Lauren Migliore.
M&A activity grew in 2010, and we expect deal volume to remain strong in 2011.
2011 was a relatively light year for biotech M&A, but it looks like activity is picking up in 2012.
Health-care analyst Lauren Migliore looks at what makes a biotech firm a likely takeout candidate and reveals our top five biotech M&A picks for 2010.
Good day everyone, and welcome to today's Bristol-Myers Squibb Fourth Quarter Earnings 2010 Earnings Release Conference Call. Today's call is being recorded.
Good day, and welcome to today's Third Quarter Earnings 2010 Earnings Release Conference Call. This call is being recorded.
Client events are essential for maintaining a strong book of business. Financial planners offered several pieces of specific advice for advisors interested in holding great events.
©2012 Morningstar Advisor. All right reserved.